20-Nov-2026 08:18:13

ALKEMGeneral news

Nomura on Alkem Labs

Buy, TP Rs 6800 Daman site issued warning letter Limited earnings impact; stock underperformed since OAI classification Issuance of warning letter is an escalation as it suggests that FDA is likely not satisfied with response following issuance of Form 483 Think a resolution could take up to 24 months Daman contributes 45% to co’s US revenues, & estimate in worst case of import alert, FY28-29F earnings impact could range from 10-15% Don’t expect an import alert Think impact FDA action is priced in the stock as ALKEM is down 10% since 06 Aug 2026 when Daman site was classified as OAI vs Nifty (+3.6%) / Nifty Pharma (+6.8%).

ALKEM LABORATORIES LTD.

← Back to feed